Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer

Journal of Surgical Oncology

Volumn 105, Issue 8, 2012, Pages 773-779

  Sun, Shanshan ^a   Jiang, Yongdong ^a   Zhang, Guoqiang ^a   Song, Hongtao ^a   Zhang, Xianyu ^a   Zhang, Youxue ^a   Liang, Xiaoshuan ^a   Sun, Qian ^a   Pang, Da ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Heilongjiang Institute for Cancer Research   (China)

Author keywords

breast cancer; fibroblast growth factor receptor 2; immunohistochemistry; prognosis

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYTOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; SURVIVAL RATE;

EID: 84861098179     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22120     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, et al.: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Zhou D, Cheng SQ, Ji HF, et al.: Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer. J Cancer Res Clin Oncol 2010; 136: 1719-1727.
3. Li C, Li R, Song H, et al.: Significance of AEG-1 expression in correlation with VEGF, microvessel density and clinicopathological characteristics in triple-negative breast cancer. J Surg Oncol 2011; 103: 184-192.
4. Wang N, Ma Q, Wang Y, et al.: CacyBP/SIP expression is involved in the clinical progression of breast cancer. World J Surg 2010; 34: 2545-2552.
5. Olopade OI, Grushko TA, Nanda R, et al.: Advances in breast cancer: Pathways to personalized medicine. Clin Cancer Res 2008; 14: 7988-7999.
6. Eswarakumar VP, Lax I, Schlessinger J,: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139-149. (Pubitemid 40616112)
7. Grose R, Dickson C,: Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 2005; 16: 179-186. (Pubitemid 40616115)
8. Ingersoll RG, Paznekas WA, Tran AK, et al.: Fibroblast growth factor receptor 2 (FGFR2): Genomic sequence and variations. Cytogenet Cell Genet 2001; 94: 121-126. (Pubitemid 34203290)
9. Easton DF, Pooley KA, Dunning AM, et al.: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-1093. (Pubitemid 47014426)
10. Hunter DJ, Kraft P, Jacobs KB, et al.: A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007; 39: 870-874. (Pubitemid 47014500)
11. Liang J, Chen P, Hu Z, et al.: Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis 2008; 29: 2341-2346.
12. Matkovic B, Juretic A, Separovic V, et al.: Immunohistochemical analysis of ER, PR, HER-2, CK5/6, p63 and EGFR antigen expression in medullary breast cancer. Tumori 2008; 94: 838-844.
13. Hsu CY, Ho DM, Yang CF, et al.: Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. Am J Clin Pathol 2002; 118: 693-698.
14. Behrens C, Lin HY, Lee JJ, et al.: Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res 2008; 14: 6014-6022.
15. Remmele W, Stegner HE,: [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987; 8: 138-140.
16. Dailey L, Ambrosetti D, Mansukhani A, et al.: Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005; 16: 233-247. (Pubitemid 40616120)
17. Ribatti D, Vacca A, Rusnati M, et al.: The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine Growth Factor Rev 2007; 18: 327-334. (Pubitemid 46891290)
18. Katoh M, Katoh M,: FGF signaling network in the gastrointestinal tract (review). Int J Oncol 2006; 29: 163-168.
19. Berger W, Setinek U, Mohr T, et al.: Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. Int J Cancer 1999; 83: 415-423. (Pubitemid 29455767)
20. Ricol D, Cappellen D, El MA, et al.: Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 1999; 18: 7234-7243. (Pubitemid 30032102)
21. Katoh M,: Dysregulation of stem cell signaling network due to germline mutation, SNP, Helicobacter pylori infection, epigenetic change and genetic alteration in gastric cancer. Cancer Biol Ther 2007; 6: 832-839. (Pubitemid 351574970)
22. Tannheimer SL, Rehemtulla A, Ethier SP,: Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE. Breast Cancer Res 2000; 2: 311-320. (Pubitemid 32223612)
23. Adnane J, Gaudray P, Dionne CA, et al.: BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 1991; 6: 659-663. (Pubitemid 21924133)
24. Moffa AB, Ethier SP,: Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. J Cell Physiol 2007; 210: 720-731. (Pubitemid 46188288)
25. Koziczak M, Holbro T, Hynes NE,: Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004; 23: 3501-3508. (Pubitemid 38658416)
26. Lu P, Ewald AJ, Martin GR, et al.: Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis. Dev Biol 2008; 321: 77-87.
27. Giulianelli S, Cerliani JP, Lamb CA, et al.: Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int J Cancer 2008; 123: 2518-2531.
28. Tsimafeyeu I, Demidov L, Stepanova E, et al.: Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma. Scand J Urol Nephrol 2011; 45: 190-195.
29. Tamaru N, Hishikawa Y, Ejima K, et al.: Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer. Lab Invest 2004; 84: 1460-1471. (Pubitemid 39482163)
30. Pichon MF, Broet P, Magdelenat H, et al.: Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 1996; 73: 1545-1551. (Pubitemid 26235381)
31. Pierga JY, Mouret E, Dieras V, et al.: Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 2000; 83: 1480-1487.
32. Meyer KB, Maia AT, O'Reilly M, et al.: Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 2008; 6: e108.
33. Pond AC, Herschkowitz JI, Schwertfeger KL, et al.: Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res 2010; 70: 4868-4879.
34. Carter CL, Allen C, Henson DE,: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-187. (Pubitemid 19032001)
35. Ogawa Y, Chung YS, Nakata B, et al.: Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen. Br J Cancer 1995; 71: 1297-1301.